P2X3 and P2X2/3 are highly expressed in bone cancer pain animals and induce pain, while a P2X3 receptor antagonist (A-317491) can reduce P2X3 and P2X2/3 overexpression and inhibit early bone cancer pain. Here, P2RX2 is linked to bone neoplasm.